Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEODISCO: Neoadjuvant Gemcitabine/Cisplatin + Pembrolizumab vs Upfront Surgery in Cholangiocarcinoma
NCT06923475Phase 3Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, gemcitabine and Cisplatin micelle injection (HA132) in extrahepatic cholangiocarcinoma (eCCA) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Event Free Survival at 18 months. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
extrahepatic cholangiocarcinoma (eCCA)
Beyond the preview
Go deeper on NCT06923475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923475.